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OBJECTIVE—Obesity and type 2 diabetes are national and
worldwide epidemics. Because currently available antiobesity
and antidiabetic drugs have limited efﬁcacy and/or safety con-
cerns, identifying new medicinal agents, such as ginsenoside
Rb1 (Rb1) as reported here, offers exciting possibilities for
future development of successful antiobesity and antidiabetic
therapies.
RESEARCH DESIGN AND METHODS—Changes in feeding
behavior after acute intraperitoneal administration of Rb1 and
the effects of intraperitoneal Rb1 for 4 weeks on body weight,
energy expenditure, and glucose tolerance in high-fat diet
(HFD)-induced obese rats were assessed. We also examined
the effects of Rb1 on signaling pathways and neuropeptides in
the hypothalamus.
RESULTS—Acute intraperitoneal Rb1 dose-dependently sup-
pressed food intake without eliciting signs of toxicity. This
inhibitory effect on feeding may be mediated by central mecha-
nisms because Rb1 stimulated c-Fos expression in brain areas
involved in energy homeostasis. Consistent with this, Rb1 acti-
vated the phosphatidylinositol 3-kinase/Akt signaling pathway
and inhibited NPY gene expression in the hypothalamus. Four-
week administration of Rb1 signiﬁcantly reduced food intake,
body weight gain, and body fat content and increased energy
expenditure in HFD-induced obese rats. Rb1 also signiﬁcantly
decreased fasting blood glucose and improved glucose tolerance,
and these effects were greater than those observed in pair-fed
rats, suggesting that although Rb1’s antihyperglycemic effect is
partially attributable to reduced food intake and body weight;
there may be additional effects of Rb1 on glucose homeostasis.
CONCLUSIONS—These results identify Rb1 as an antiobesity
and antihyperglycemic agent. Diabetes 59:2505–2512, 2010
O
besity has reached epidemic proportions and
created serious public health problems in the
U.S. Obesity is a major risk factor for type 2
diabetes, cardiovascular problems, and some
forms of cancer. Although efforts to address the environ-
mental and genetic factors responsible for the “epidemic”
must continue, and because currently available antiobesity
and antidiabetic drugs have limited efﬁcacy and/or safety
concerns, developing safe and effective medicinal agents,
particularly with the dual properties of controlling body
weight and reducing blood glucose, offers exciting possi-
bilities for developing successful therapies.
Panax ginseng is a highly valued herb in much of the
world, and the root of the ginseng plant has been used as
an herbal remedy in Eastern Asia for over 2000 years. The
word “panax” is derived from “panacea,” which means
cure-all and longevity. Ginseng and its constituents have
historically been ascribed as general tonics and adapto-
gens to maintain homeostasis and the body’s resistance to
adverse factors. The efﬁcacy of ginseng was recognized in
the West by the 18th century, and now ginseng is one of
the most popular and top-selling herbals in the U.S. (1,2).
Modern pharmacological studies indicate that ginseng
extracts possess a wide range of effects, including enhanc-
ing learning and memory, reducing anxiety, reducing can-
cer risk, and improving immunomodulation (3–6).
Chronic administration of an extract of ginseng root
signiﬁcantly reduced body weight, fat mass, and serum
lipids in diet-induced obese rats (7,8), and extracted
ginseng has also been reported to ameliorate hyperglyce-
mia in animals and humans (9–12). In one report, both
diabetic and nondiabetic subjects taking an extract of
ginseng had stabilized postprandial glycemia, suggesting
that ginseng may also beneﬁt healthy individuals (13). A
shortcoming of the existing literature is that the speciﬁc
compound(s) within extracted ginseng that have beneﬁcial
actions are unknown.
Although the components in ginseng root vary across
sources and species, ginsenoside Rb1 (Rb1) is considered the
most abundant and most important active factor (14). Rb1
has been well characterized chemically (15); it has the
structure of a tetracyclic triterpenoid with a molecular for-
mula of C54H92O23 and molecular weight of 1,109.26 (16). Rb1
has been reported to have diverse biological activities, in-
cluding facilitating acquisition and retrieval of memory (17),
scavenging free radicals (18), blocking calcium over-inﬂux
into neurons (19), and preserving the structural integrity of
the neurons (20). Rb1 also increased glucose uptake and
suppressed lipid accumulation in 3T3-L1 adipocytes and
enhanced insulin secretion from pancreatic Min6 cells (21–
23). Based on these reports, we hypothesized that Rb1 has
potent antiobesity and antidiabetic effects.
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Animals. Adult male Long-Evans rats (Harlan, Indianapolis, IN) were individ-
ually housed in a temperature-controlled vivarium on a 12/12-h light/dark
cycle (lights on at 0000 h, lights off at 1200 h). Laboratory chow (Purina 5001,
Hudson, NH) was provided ad libitum except where noted. All procedures
were approved by the Institutional Animal Care and Use Committee of the
University of Cincinnati.
Materials. Rb1 puriﬁed by high-performance liquid chromatography (HPLC)
was purchased from Jilin University in China. High-performance liquid
chromatography (Shimadzu, Kyoto, Japan) analysis was performed in our
laboratory and conﬁrmed that the Rb1 had a purity of 98% using an Rb1
standard obtained from LKT laboratories (St. Paul, MN). The antibody against
c-Fos was from Chemicon (Millipore, Billerica, MA), and antibodies for p-Akt
and Akt were from Cell Signaling Technology (Beverly, MA).
Food intake in ad libitum–fed and fasted rats. Two studies were con-
ducted to determine the effects of acute administration of Rb1 on food intake.
In the ﬁrst study, ad libitum–fed rats received intraperitoneal Rb1 in saline at
doses of 0, 2.5, 5, 10, or 20 mg/kg; in the second study, 24-h–fasted rats
received intraperitoneal Rb1 at a dose of 10 mg/kg. The Rb1 or saline was
administered at the beginning of dark, and food intake was recorded after 2,
4, 6, 8, 10, and 24 h.
Conditioned taste aversion assessment. To determine whether Rb1 elicits
visceral illness, we used a standard two-bottle preference paradigm (24,25).
Rats (n  24) were adapted to 2-h daily access to water (available in two
bottles) for 5 days. On day 6, rats were given 0.15% saccharin in water in each
bottle for the 2-h period instead of water and then were injected with either
Rb1 (40 mg/kg i.p.) or vehicle (n  8/group). A third group (n  8) received
LiCl as a positive control (0.15 mol/l; 127 mg/kg i.p.). On day 7, animals had
water in both bottles during the 2-h session, and on the test day (day 8), rats
were presented with one bottle containing saccharin and one containing water
for 24 h. Saccharin preference ratio was calculated as the amount of saccharin
consumed divided by the total consumption of both liquids over 2 and 24 h.
c-Fos expression in the brain. After a 4-h light-phase food restriction,
animals received intraperitoneal Rb1 (10 mg/kg) or saline at the onset of dark.
No food was provided after injection. Rats were anesthetized and perfused
with 4% paraformaldehyde for c-Fos immunostaining 2 h after the injections
using a previously published method (26). Free-ﬂoating sections (30 m) were
cut through the regions of the brainstem and the hypothalamus (27) and
incubated with primary rabbit anti–c-Fos antibody (1:10,000, overnight at
4°C), biotinylated donkey anti-rabbit antibody (Vector, 1:300, 2 h), and
avidin-biotin-peroxidase complex (Vector, 2 h) with PBS wash in-between.
The sections were then developed by diaminobenzidine with nickel sulfate to
produce a dark-purple reaction product. Speciﬁc staining was abolished by
omission of primary antiserum.
The number of c-Fos–positive cells was quantiﬁed by a blind observer in
the following areas: nucleus of the solitary tract (NTS) (13.80 from bregma)
and the hypothalamic arcuate (ARC) (2.30 from bregma), ventromedial
(VMH) (2.56 from bregma), and lateral nuclei (LH) (1.88 from bregma).
For each animal, the number of c-Fos–positive cells was an average value of
four to ﬁve sections. Data for c-Fos activation in all of these areas were
bilaterally assessed under a light microscope with low magniﬁcation (40)
and were presented as the total number per section.
High-fat diet–induced obese rats. A total of 36 rats were fed with a high-fat
diet (HFD) containing 20 g fat (19 g butter oil and 1 g soybean oil)/100 g diet
prepared by Research Diets (category number D03082706; New Brunswick,
NJ) for 13 weeks, as described previously (28). The rats became obese (mean
body weight 596 g) and were divided into three groups of comparable body
weight. Groups 1 and 2 received intraperitoneal saline or Rb1 (10 mg/kg),
respectively, daily for 28 days and had free access to the same HFD. Because
Rb1-treated rats had reduced food intake, an HFD pair-fed group was included
as a control. These rats were given the HFD but with an amount limited to the
average daily consumption of Rb1-treated rats. Food intake and body weight
were recorded daily, and energy expenditure and glucose tolerance were
assessed at speciﬁed times. At the end of the experiment, the rats were killed
after a 6-h fast, and blood and tissues were collected and stored at 80°C for
further analyses as detailed below.
Measurement of intestinal fat absorption. A noninvasive method was
used to measure intestinal fat absorption (29). Feces were isolated from three
rats in each group on day 24 of Rb1 treatment, and the fatty acids in the feces
were analyzed and quantiﬁed with a heptadecanoic acid standard by gas
chromatography (29).
Measurement of plasma samples. Plasma triglyceride and cholesterol levels
were measured using Inﬁnity reagent (Thermo, Middletown, VA). Free fatty acid
content was measured using NEFA reagent (Wako, Richmond, VA). Leptin was
measured using commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Millipore, St. Charles, MO). The levels of alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and creatinine were assessed with
VITROS Chemistry Products Calibrator Kit 3 and VITROS Chemistry Systems
(Ortho-Clinical Diagnostics, Buckinghamshire, U.K.).
Indirect calorimetry. Energy expenditure was assessed with a Physioscan
Open Circuit Calorimeter System (Accuscan Instruments, Columbus, OH).
The rats were maintained on their respective diet regimens and placed in
individual metabolic chambers for 24 h (24). Data were sampled every 60 s.
Body fat/lean composition determination. Body fat was assessed by
nuclear magnetic resonance (NMR) (EchoMRI; EchoMedical Systems, Hous-
ton, TX). Unanesthetized rats were placed in a restraint tube and inserted into
the nuclear magnetic resonance, providing estimates of total lean tissue, fat
tissue, and water.
Histological analysis and morphometry. Adipose tissue was ﬁxed in 10%
formalin for 1 month and then embedded with parafﬁn. Tissue sections (10
m) were cut with a microtome (Leica, Germany) and mounted on superfrost/
plus microscope slides. After being air-dried, they were stained with hema-
toxylin and eosin and photographed at 100 magniﬁcation. At least two ﬁelds
per slice and six slices per fat mass were analyzed for the purpose of
quantifying adipocyte size.
Intraperitoneal glucose tolerance test. On day 28 of treatment, rats were
fasted overnight and given intraperitoneal glucose (1 g/kg, at 1000 h). Blood
samples were taken from the tail vein, and glucose was assessed with a
glucometer (Freestyle; Abbott Diabetes Care, Alameda, CA) at 0 (fasting), 15,
30, 60, 120, and 180 min after glucose administration. Plasma insulin was
measured in the same samples with a rat insulin ELISA kit (Millipore).
Assessment of the phosphatidylinositol 3-kinase signaling pathway.
Primary neuronal cells, prepared from hypothalami of embryos and cultured
as previously described (30), were treated with different concentrations of
Rb1 (0.1–100 mol/l) for 4 h, or with 10 mol/l Rb1 for a range of times (0–4
h). The proteins from the cultured neuronal cells, as well as the proteins from
the hypothalamus of HFD-induced obese rats with different treatments, were
then extracted for measuring phosphorylated Akt (p-Akt) and total Akt levels
by Western immunoblotting as described previously (30).
qPCR for neuropeptide mRNA measurement. Total RNA (100 ng), ex-
tracted from hypothalami of HFD-induced obese rats with different treatments
using Tri Reagent (Molecular Research Center, Cincinnati, OH), was reverse-
transcribed to ﬁrst-strand complementary DNA (GE Healthcare Bio-Sciences,
Piscataway, NJ). Quantitative real-time PCR (qPCR) was performed in a 25-l
ﬁnal reaction volume with an iCycler iQ Detection System using iQ SYBR
Green Supermix (Bio-Rad Laboratories, Hercules, CA). qPCR conditions and
sequences of the primers for measuring mRNA levels of the neuropeptides,
including proopiomelanocortin (POMC), neuropeptide Y (NPY), and agouti-
related protein (AgRP), were described previously (24).
Statistical analysis. Data were analyzed using parametric statistics (Sigma
Stat version 3.1). Two-way ANOVA and two-way repeated-measures ANOVA
followed by the Student-Newman test were used for analysis of food intake,
body weight, energy expenditure, blood glucose, and plasma insulin levels.
For other comparisons, one-way ANOVA was followed by the Student-
Newman test. Data are presented as means  SE. Values of P  0.05 were
considered signiﬁcant.
RESULTS
Acute Rb1 administration inhibited food intake. In-
traperitoneal Rb1 at doses 5 mg/kg signiﬁcantly reduced
food intake in ad libitum–fed rats (Fig. 1A). In a subse-
quent experiment, intraperitoneal Rb1 (10 mg/kg) signiﬁ-
cantly decreased food intake in 24-h–fasted rats (Fig. 1B).
This effect was present at 4 h and lasted for at least 6 h
more. There were no signiﬁcant changes of food intake or
body weight by 24 h after Rb1 treatment in any condition
(Fig. 1C, D, and E).
Reduction of food intake induced by Rb1 was not
associated with illness. Rats that received saccharin
paired with Rb1 (40 mg/kg i.p.) had comparable preference
for saccharin as saline controls at both 2 and 24 h after
treatments. In contrast, animals that received LiCl con-
sumed signiﬁcantly less saccharin than controls (Fig. 1F).
Rb1 induced brain c-Fos expression. Rb1 signiﬁcantly
induced c-Fos expression in the hindbrain NTS and the ARC
and VMH in the hypothalamus, but not in the LH (Fig. 2).
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HFD-induced obese rats. When Rb1 (10 mg/kg) was
administered intraperitoneally in HFD-induced obese rats,
it gradually and signiﬁcantly decreased food intake during
the ﬁrst week, and the reduced food intake was apparent
throughout the 25-day observation period (Fig. 3A). Body
weight gain was signiﬁcantly suppressed beginning on day
8 and continued until the end of the experiment (Fig. 3B).
Body weight change was comparable between Rb1-treated
rats and HFD pair-fed rats during the ﬁrst 20 days of
treatment. However, beginning after the third week, the
weight of the Rb1-treated rats became signiﬁcantly re-
duced relative to that of the pair-fed rats (Fig. 3B). No side
effects, such as diarrhea, were observed. In addition,
HFD-fed rats, with or without Rb1, had similar levels of
AST, ALT, and creatinine (Table 1).
Rb1 increased energy expenditure in HFD-induced
obese rats. Energy expenditure measured by indirect
calorimetry on day 26 of Rb1 treatment was signiﬁcantly
higher during the dark phase relative to saline controls
(Fig. 3C and D). No difference in respiratory quotient
occurred among the three groups (data not shown).
Rb1 reduced body fat in HFD-induced obese rats.
Consistent with the reduced body weight, Rb1-treated rats
had reduced body fat compared with saline controls (Fig.
4B versus 4A). Whereas fat composition was slightly
reduced in HFD pair-fed rats, only Rb1-treated rats had a
signiﬁcantly lower percentage of fat compared with con-
trols. There were no differences in lean tissue mass, body
water, or brown adipose tissue mass among groups (Table
1). To determine whether there was regionally speciﬁc fat
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treatment, but not pair-feeding, signiﬁcantly decreased
visceral fat, including epididymal, retroperitoneal, and
mesenteric fat, as well as inguinal fat compared with
saline controls (Fig. 4C, D, and E). Rb1-induced reduction
of adipose tissue weight was mainly due to decreased
adipocyte size, with adipocytes from epididymal and in-
guinal fat pads being signiﬁcantly smaller in Rb1-treated
rats than in the saline controls (Fig. 4F and G). The
reduced body fat was mirrored by a concomitant fall in
plasma leptin (Fig. 4H). Rb1 treatment also signiﬁcantly
reduced the levels of plasma triglyceride and cholesterol,
but not nonesteriﬁed fatty acids (Table 1). There were no
differences in these parameters between Rb1-treated and
HFD pair-fed rats.
Rb1 did not affect lipid absorption in HFD-obese
rats. No signiﬁcant differences in lipid content (%) of
the feces were found between Rb1 and saline-treated
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TABLE 1
Plasma levels of AST, ALT, and creatinine, and body fat and lean composition and lipid proﬁles in HFD-induced obese rats with or
without Rb1 treatment
Saline Rb1 Pair-fed
AST (U/l) 119.1  13.7 125.0  10.9 102.8  10.6
ALT (U/l) 40.0  5.8 37.1  3.6 33.7  3.5
Creatinine (mg/dl) 0.395  0.04 0.404  0.04 0.392  0.04
Fat mass (g) 166.3  7.8 133.6  6.1* 140.7  6.2†
Lean mass (g) 377.6  9.3 382.9  4.9 379.2  7.6
Brown adipose tissue (g) 0.94  0.07 0.92  0.08 0.84  0.05
Water (g) 338.1  8.27 343.1  4.47 339.8  6.81
Triglyceride (mg/dl) 125.1  12.71 92.4  7.02† 77.8  7.57*
Cholesterol (mg/dl) 100.6  7.11 72.5  6.0† 80.8  3.52
Nonesteriﬁed fatty acids (mEq/l) 0.442  0.035 0.439  0.023 0.371  0.021
Data are means  SE. *P  0.01, †P  0.05 vs. HFD obese rats treated with saline.
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lipid absorption.
Rb1 ameliorated hyperglycemia and improved glu-
cose tolerance in HFD-induced obese rats. After 4
weeks of 10 mg/kg Rb1 treatment, fasting plasma glucose
in HFD-induced obese rats was reduced (Fig. 5A), and
glucose levels during the intraperitoneal glucose tolerance
test were reduced by Rb1 all time points from 15 to 180
min (Fig. 5B). The area under the curve in Rb1-treated rats
was decreased by 30% compared with vehicle controls
(Fig. 5C). Hence, peripheral Rb1 is efﬁcacious in amelio-
rating diabetic symptoms associated with obesity. There
was also signiﬁcantly lower fasting insulin in Rb1-treated
rats, compared with saline controls (Fig. 5D). Fasting
glucose levels and glucose tolerance were improved to a
greater extent by Rb1 than by pair-feeding (Fig. 5A and C).
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epididymal and inguinal fat tissues. The size of adipocytes was calculated and represented by total adipocyte area (n  6). Rb1 treatment
resulted in reduced average adipocyte size (G). Rb1 decreased plasma leptin (H). *P < 0.05; **P < 0.01 vs. saline controls. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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Akt signaling pathway in hypothalamus. Phosphory-
lation of Akt (pAkt) in primary cultured neurons was
stimulated by Rb1 at doses of 10 mol/l (Fig. 6A), with
the acute effect of Rb1 on phosphorylation of Akt
beginning after 2 h (Fig. 6B). This effect was conﬁrmed
in HFD-induced obese rats, i.e., chronic Rb1 treatment,
but not pair-feeding, signiﬁcantly increased hypotha-
lamic pAkt levels (Fig. 6C).
Rb1 reduced NPY gene expression in HFD-induced
obese rats. Rb1 signiﬁcantly reduced hypothalamic NPY
mRNA (Fig. 6D), but not AgRP mRNA (Fig. 6E), levels
compared with saline controls. Although there was a trend
toward increased POMC gene expression after Rb1 treat-
ment, it was not signiﬁcant (Fig. 6F).
DISCUSSION
Ginseng root has historically been ascribed to be a general
tonic or adaptogen to maintain the body’s resistance to
adverse factors and homeostasis. Modern studies have
demonstrated that most of the pharmacological actions of
extracted ginseng are attributed to ginsenosides (31), and
30 of them have been isolated (32). As a class of
compounds, ginsenosides have been demonstrated to be
useful in the control of body weight (7,8,11) and blood
glucose (9–12,33–36). However, the complications caused
by the multiple known and unknown ingredients in gin-
seng prevent its application to clinical usage as an alter-
native medicine to treat obesity and diabetes. The present
studies extend previous observations and indicate that
ginsenoside Rb1 may prove particularly important in treat-
ing obesity and diabetes.
We have demonstrated for the ﬁrst time that acute
intraperitoneal administration of Rb1 signiﬁcantly sup-
presses food intake. This effect is dose dependent and
does not elicit malaise, in that an effective dose of Rb1 did
not cause a conditioned taste aversion. Hence, visceral
illness is likely not a factor in the feeding suppressive
actions of peripherally administered Rb1.
c-Fos expression has been used as an index of neuronal
activity in rats and mice (37,38). Using c-Fos immunohis-
tochemistry (39), we observed that Rb1, at an effective
dose (10 mg/kg) in reducing food intake, signiﬁcantly
induced c-Fos expression in the hindbrain NTS and in the
ARC and VMH of the hypothalamus, but not in the LH.
Many endogenous factors inﬂuence satiation via signals
passing from abdominal viscera to the NTS through the
vagus nerve, with the signals then being relayed anteriorly
to the hypothalamus and other brain areas (40–42). There-
fore, one possible explanation of the effect of intraperito-
neal Rb1 on food intake is via alteration of peripheral
afferent neural activity. There is also a previous report that
food intake was reduced by acute intra-third ventricular
(i3vt) administration of Rb1 (43), implying that central
neural circuits are sensitive to Rb1 and that peripherally
administered Rb1 may penetrate the brain reaching local
circuits that inﬂuence food intake and body weight. Be-
cause the blood-brain barrier is a major controlling site for
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the capability of Rb1 to penetrate the blood-brain barrier
will be an important question for future research. Since
ginseng and its extract are generally consumed orally, the
implication is that its active ingredients are able to pene-
trate membranes.
Epidemiological studies have identiﬁed a positive cor-
relation between average dietary fat intake and the inci-
dence of obesity. To determine the effect of chronic Rb1
treatment on obesity, we used an HFD-induced obese rat
model (28). Those studies conﬁrmed Rb1’s effect to reduce
food intake, especially during the early period of treat-
ment, and to be maintained throughout the observation
period, such that Rb1’s anorectic capacity was still evident
with sustained administration.
Rb1-treated obese rats behaved normally with no obvi-
ous health problems (i.e., no side effects, such as diarrhea
were observed during the period of Rb1 treatment). To
evaluate whether chronic Rb1 had nonspeciﬁc toxic ef-
fects that could complicate the interpretation of the re-
sults, plasma levels of ALT, AST, and creatinine were
assessed at the end of the experiment. AST and ALT are
enzymes that become elevated with liver disease or injury.
Creatinine is a byproduct of muscle metabolism and is
excreted by the kidneys, and elevated levels can indicate
kidney disease, urinary tract obstruction, or dehydration.
Animals fed HFD, with or without Rb1, had similar levels
of AST, ALT, and creatinine (Table 1), indicating that
chronic treatment with Rb1 did not have any appreciable
toxic effect on the liver or kidney.
In parallel with the reduction of food intake, there was
a signiﬁcant decrease in body weight in rats treated with
Rb1, compared with vehicle controls. More importantly,
the reduced body weight was mainly due to a selective
reduction of body fat, leaving lean mass unchanged.
Pair-fed rats weighed more than the rats treated with Rb1
after the ﬁrst 3 weeks of treatment, implying that Rb1’s
effect on body weight is not simply secondary to a
reduction of food intake. This is consistent with our
observation that chronic treatment with Rb1 signiﬁcantly
increased energy expenditure relative to the saline control
group. Although the difference in energy expenditure
between Rb1 and pair-fed groups did not reach statistical
signiﬁcance during the 1-day test, a slight but persistent
increase in energy expenditure induced by Rb1 may ex-
plain why Rb1-treated rats had less body weight gain than
HFD pair-fed rats beginning after 21 days when food
intake was the same for both groups. These observations
suggest that attenuated weight gain associated with Rb1
treatment is due to a combination of reduced food intake
and increased energy expenditure.
One possible explanation for the reduced fat mass could
be reduced fat absorption induced by Rb1. However, this
seems unlikely because there was no signiﬁcant difference
in fecal lipid excretion between Rb1 and saline-treated
rats, implying that Rb1 did not signiﬁcantly affect lipid
absorption.
Obese subjects are often hyperglycemic and glucose
intolerant, and this could be due to increased insulin
resistance and/or defects in insulin secretion. Chronic Rb1
treatment signiﬁcantly reduced fasting glucose and im-
proved impaired glucose tolerance. More importantly,
these effects were greater than those observed in pair-fed
controls, implying that there are effects of Rb1 on glucose
homeostasis beyond those due to decreased food intake
and body weight. One way to improve insulin sensitivity is
through an increase of tissue glucose uptake, and this
possibility is supported by previous in vitro studies dem-
onstrating that Rb1 signiﬁcantly stimulated basal and
insulin-mediated glucose uptake in a time- and dose-
dependent manner in both 3T3-L1 adipocytes and C2C12
myotubes (21). The effect was mediated through increased
gene expression of GLUT4 and increased GLUT4 translo-
cation to the cell surface (21). Although Rb1-induced
reduction of fasting blood glucose was not accompanied
by increased plasma insulin in HFD-obese rats, it cannot
be ruled out that Rb1 may stimulate insulin secretion
because the improved insulin sensitivity requires less
insulin to maintain blood glucose level. This possibility is
supported by a report that Rb1 promoted glucose-stimu-
lated insulin secretion from Min6 cells, a mouse insuli-
noma cell line (23).
Phosphatidylinositol 3-kinase is an intracellular signal-
ing pathway that plays a pivotal role in many essential
cellular processes. Using primary cultured neuronal cells,
prepared from hypothalami of embryos (30), we found
that Rb1 signiﬁcantly and dose-dependently (0.1–100
mol/l) activates the phosphatidylinositol 3-kinase signal-
ing pathway beginning after2ho ftreatment. This effect
was conﬁrmed in HFD-induced obese rats (i.e., chronic
Rb1 treatment, but not pair-feeding, signiﬁcantly increased
hypothalamic pAkt levels, indicating that Rb1 may inﬂu-
ence metabolic parameters, at least in part, by regulating
this signaling pathway in the brain).
Central nervous system circuits involved in food intake
can be conceptually divided into anabolic and catabolic
systems. NPY, AgRP, and POMC are key peptides in these
systems, respectively (46), and it is the balance between
these systems that ultimately determines the animal’s
ingestive behavior and energy expenditure (46,47).
Chronic Rb1 treatment signiﬁcantly reduced NPY, but not
AgRP, mRNA in the hypothalamus of HFD-obese rats,
implying that Rb1 exerts its anorectic action, at least
partially, by inhibiting the activity of the NPY system.
POMC mRNA was nonsigniﬁcantly increased.
The molecular mechanisms as to how Rb1 acts on cells are
not clear. Recent reports suggest that Rb1 might act as a
phytoestrogen and exert estrogen-like activity through estro-
gen receptors (ERs) (16,48). Rb1 activated both ER and
ER	 dose-dependently, and the activation was inhibited by
ICI 182,780, an estrogen receptor antagonist, indicating that
these effects were mediated through the ER. Treatment with
Rb1 increased ER expression in MCF-7 cells and of AP-1–
driven luciferase genes in COS cells (16), but these actions
are likely independent of a direct ER association because
Rb1 did not displace speciﬁc binding of [
3H]17	-estradiol
from estrogen receptors in MCF-7 whole-cell ligand binding
assays (16). These observations suggest that Rb1 is function-
ally similar to 17	-estradiol. Because estrogen signaling plays
an important role in the control of energy homeostasis,
whether ER mediates the catabolic action of Rb1 will require
further study.
In summary, we have demonstrated that intraperitoneal
Rb1 signiﬁcantly reduces food intake without causing
malaise in ad libitum–fed or fasted rats. Moreover, chronic
intraperitoneal treatment with Rb1 signiﬁcantly reduced
food intake and body weight gain and increased energy
expenditure in HFD-induced obese rats. Rb1 also signiﬁ-
cantly decreased fasting blood glucose and improved
glucose tolerance to a greater extent than pair-feeding in
the HFD-induced obese rats, raising the possibility that
Rb1 has important effects on glucose homeostasis. These
Ye XIONG AND ASSOCIATES
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